For the fiscal quarter ending March 2026, Replimune Group Inc is expected to report a consensus loss of $0.73 per share on zero revenue, with the current stock price of $10.00 notably exceeding the average analyst price target of $7.86. The primary focus for the June 25 report is the company’s regulatory roadmap and the specific timeline for its third RP1 Biologics License Application (BLA) resubmission following the FDA’s second rejection in April.
Recent discussions with the FDA have established a path forward for an 'urgent' review, which has fueled a significant technical recovery in the share price. However, with cash reserves only sufficient to fund operations through late 2026, investors remain attentive to the firm's quarterly burn rate and any signals of upcoming capital requirements.